[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 6, 1963

Attempt to Remove Thorium by Use of Chelating Agent

Author Affiliations

Boston; Cambridge, Mass.; Boston

Chief Medical Resident (Dr. Fontaine), Assistant Resident in Medicine (Dr. Barber), and Chief of Medical Service (Dr. Graham), Faulkner Hospital, Boston; Research Biophysicist (Dr. Maletskos), Radioactivity Center, Department of Physics, Massachusetts Institute of Technology, Cambridge, Mass.; and Physicist (Dr. Webster), Department of Radiology, Massachusetts General Hospital, Boston.

JAMA. 1963;184(1):55. doi:10.1001/jama.1963.73700140008018
Abstract

COLLOIDAL thorium dioxide (Thorotrast) was used extensively from 1928 until about 1950 to perform arteriograms, urograms, fistulagrams, and to outline focal lesions of the liver. The radiation dose from the amount usually injected is sufficient to warrant the expectation that neoplasms might develop in tissues chronically exposed to this agent which is almost totally retained in the body and remains radioactive for many years.

The first example of a malignant tumor in man induced by thorium dioxide was reported in 1947.1 By March of 1962, 55 well-documented examples of Thorotrast-induced malignancy in man had been reported.2-8

Recently, chelating agents have been found useful in removing heavy metals from humans. Animal and human experiments9-11 suggest that diethylenetriaminepentacetic acid (DTPA) may be effective in the removal of thorium, although there are indications that the ionic form of thorium would be more susceptible than the colloidal form.

Materials and 

First Page Preview View Large
First page PDF preview
First page PDF preview
×